| December 31, | ||||||||
| 2023 | 2022 | |||||||
| Outstanding redeemable convertible preferred units | 41,813,375 | 41,478,621 | ||||||
| Outstanding profits interests | 9,488,776 | 7,516,073 | ||||||
| Units available for grants under 2019 Equity Incentive Plan | 5,115,389 | 7,088,092 | ||||||
| Total common units reserved for future issuance | 56,417,540 | 56,082,786 | ||||||
| Stock | Non-Equity Incentive Plan | All Other | ||||||||||||||||||||||||
| Name and Principal | Salary | Bonus(1) | Awards(2) | Compensation(3) | Compensation(4) | Total | ||||||||||||||||||||
| Position | Year | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||||
| Brian C. Thomas, Ph.D. | 2023 | 516,667 | 20,000 | 6,966,519 | 288,600 | 34,069 | 7,825,855 | |||||||||||||||||||
| Chief Executive Officer | 2022 | 500,000 | 100,000 | 1,223,129 | 318,250 | 15,250 | 2,156,629 | |||||||||||||||||||
| Jian Irish, Ph.D., MBA | 2023 | 465,000 | 15,000 | 1,783,211 | 231,449 | 18,368 | 2,513,028 | |||||||||||||||||||
| President and Chief Operating Officer | 2022 | 450,000 | 52,000 | 313,084 | 260,354 | 8,990 | 1,084,428 | |||||||||||||||||||
| Sarah Noonberg, M.D., Ph.D. | 2023 | 388,231 | 15,000 | 1,447,782 | 169,963 | 18,300 | 2,039,276 | |||||||||||||||||||
| Chief Medical Officer | ||||||||||||||||||||||||||
